17 active not recruiting, 12 completed, 6 recruiting, 2 suspended. 31 Phase 2, 9 Phase 1, 3 Phase 3.
Follow Cabozantinib S-malate: new trials by email Literature Review of Cabozantinib S-malate trials Research Report on Cabozantinib S-malate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 92 | 2025-11-17 | 2026-10-16 |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 50 | 2024-02-19 | 2026-10-19 |
| Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial Atezolizumab, Biospecimen Collection, Bone Scan - Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 200 | 2023-03-24 | 2026-10-01 |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Bone Scan, Cabozantinib S-malate, Cisplatin - High Grade Osteosarcoma, Localized Osteosarcoma | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 1122 | 2023-03-03 | 2026-10-16 |
| Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Atezolizumab, Biopsy, Cabozantinib S-malate - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2022-12-10 | 2022-12-14 | |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-20 |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Anal Melanoma, Bladder Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 101 | 2022-08-11 | 2026-08-04 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-01 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Atezolizumab, Cabozantinib S-malate - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Utah | 31 | 2022-03-29 | 2026-10-14 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2021-11-01 | 2026-03-05 |
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment - Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma | Phase 1 | Recruiting | Emory University | 32 | 2021-07-23 | 2026-04-29 |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer Cabozantinib S-malate, Pembrolizumab - Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Phase 2 | Terminated | University of Washington | 2 | 2021-04-20 | 2023-04-05 |
| Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-11-04 | 2026-09-08 |
| Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors Cabozantinib S-malate, Ipilimumab, Nivolumab - Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2020-08-06 | 2026-09-22 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 98 | 2020-07-29 | 2026-09-28 |
| Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 117 | 2020-07-13 | 2026-10-22 |
| Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities Cabozantinib S-malate, Radiation Therapy - Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities | Phase 1 / Phase 2 | Terminated | University of Washington | 6 | 2020-06-01 | 2025-07-17 |
Showing 20 of 40. Sign in to see all of them.
Carcinoma, Renal Cell (10) · Carcinoma, Hepatocellular (5) · Ovarian Neoplasms (4) · Carcinoma, Medullary (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Fallopian Tube Neoplasms (3) · Melanoma (3) · Osteosarcoma (3) · Prostatic Neoplasms (3) · Thyroid Neoplasms (3) · Urethral Neoplasms (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma, Follicular (2) · Adrenocortical Carcinoma (2)
National Cancer Institute (NCI) (31) · Emory University (2) · M.D. Anderson Cancer Center (2) · University of Washington (2) · City of Hope Medical Center (1) · OHSU Knight Cancer Institute (1) · University of Utah (1)
United States (38) · Canada (9) · Australia (1) · France (1) · Guam (1) · New Zealand (1) · Puerto Rico (1)
Joel W Neal (3) · Andrea B Apolo (2) · Sumanta K Pal (2) · Adel Kardosh, M.D., Ph.D. (1) · Adel Mandl (1) · Alexander N Shoushtari (1) · Antoine Italiano (1) · Anwaar Saeed (1) · Apostolia M Tsimberidou (1) · Ari J Rosenberg (1) · Benjamin L Maughan (1) · Bhavana Konda (1) · Camilo Jimenez (1) · Gentry George King (1) · Haiying Cheng (1)
PMID 31401903, PMID 35031545, PMID 37146227, PMID 27825638, PMID 28549224, PMID 28817373, PMID 29550566, PMID 30587441, PMID 30915273, PMID 31371341, PMID 31399500, PMID 31992589, PMID 32078813, PMID 32827353, PMID 32915679, PMID 33152282, PMID 33170593, PMID 33592176, PMID 33604999, PMID 35288469, PMID 37185961, PMID 38608693, PMID 38942995, PMID 38954785, PMID 39133806, PMID 39255440, PMID 39282913, PMID 41524552, PMID 41968073, PMID 42507969, PMID 42847673
U10CA180821 (9), U10CA180820 (3), U10CA180888 (3), N01CM00038 (2), N01CM00071 (2), P30CA033572 (2), P30CA138292 (2), U10CA031946 (2), U10CA180868 (2), U10CA180886 (2), UM1CA186644 (2), UM1CA186712 (2), N01CM00032 (1), N01CM00039 (1), N01CM00070 (1)